Yann Bergé

408 total citations
17 papers, 323 citations indexed

About

Yann Bergé is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Yann Bergé has authored 17 papers receiving a total of 323 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 8 papers in Molecular Biology. Recurrent topics in Yann Bergé's work include HER2/EGFR in Cancer Research (5 papers), Colorectal Cancer Treatments and Studies (5 papers) and Cancer Treatment and Pharmacology (4 papers). Yann Bergé is often cited by papers focused on HER2/EGFR in Cancer Research (5 papers), Colorectal Cancer Treatments and Studies (5 papers) and Cancer Treatment and Pharmacology (4 papers). Yann Bergé collaborates with scholars based in France, Switzerland and Spain. Yann Bergé's co-authors include Jean‐Pierre Delord, Jean‐Charles Soria, Luigi Manenti, Carlos Gomez‐Roca, Josep Tabernero, Andrés Cervantes, Antoîne Italiano, Luis Paz‐Ares, Florence Dalenc and Thomas Filleron and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

Yann Bergé

17 papers receiving 321 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yann Bergé France 10 162 154 100 47 46 17 323
Yu Kataoka Japan 6 176 1.1× 213 1.4× 99 1.0× 43 0.9× 73 1.6× 10 378
Greg Friberg United States 10 189 1.2× 259 1.7× 116 1.2× 64 1.4× 50 1.1× 15 488
Laura Kirby Australia 8 245 1.5× 169 1.1× 128 1.3× 36 0.8× 34 0.7× 11 362
Ju-Hee Bang South Korea 13 247 1.5× 127 0.8× 105 1.1× 64 1.4× 31 0.7× 17 380
J. Harrison Howard United States 7 213 1.3× 109 0.7× 75 0.8× 20 0.4× 54 1.2× 11 302
Bruce McCall United States 10 276 1.7× 108 0.7× 103 1.0× 95 2.0× 95 2.1× 14 376
Matthew R. Strickland United States 8 218 1.3× 251 1.6× 150 1.5× 33 0.7× 25 0.5× 18 475
Davide Bosso Italy 12 132 0.8× 133 0.9× 167 1.7× 41 0.9× 57 1.2× 18 366
Tim Perera Italy 5 145 0.9× 160 1.0× 77 0.8× 12 0.3× 76 1.7× 8 298
Andrej Valkov Norway 13 247 1.5× 105 0.7× 231 2.3× 113 2.4× 19 0.4× 14 406

Countries citing papers authored by Yann Bergé

Since Specialization
Citations

This map shows the geographic impact of Yann Bergé's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yann Bergé with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yann Bergé more than expected).

Fields of papers citing papers by Yann Bergé

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yann Bergé. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yann Bergé. The network helps show where Yann Bergé may publish in the future.

Co-authorship network of co-authors of Yann Bergé

This figure shows the co-authorship network connecting the top 25 collaborators of Yann Bergé. A scholar is included among the top collaborators of Yann Bergé based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yann Bergé. Yann Bergé is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Pons‐Tostivint, Elvire, Laëtitia Daubisse‐Marliac, Pascale Grosclaude, et al.. (2019). Multidisciplinary team meeting and EUSOMA quality indicators in breast cancer care: A French regional multicenter study. The Breast. 46. 170–177. 13 indexed citations
2.
Bahleda, Rastislav, Andréa Varga, Yann Bergé, et al.. (2018). Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2. British Journal of Cancer. 118(3). 344–352. 7 indexed citations
3.
Spreafico, Anna, J.P. Delord, Leticia De Mattos‐Arruda, et al.. (2015). A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies. British Journal of Cancer. 112(4). 650–659. 27 indexed citations
4.
Delord, Jean‐Pierre, Josep Tabernero, Rocio García‐Carbonero, et al.. (2013). Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma. European Journal of Cancer. 50(3). 496–505. 22 indexed citations
5.
Cassier, Philippe A., Éric Amela, Christine Chevreau, et al.. (2013). A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group. British Journal of Cancer. 109(4). 909–914. 58 indexed citations
6.
Mattos‐Arruda, Leticia De, Lillian L. Siu, Javier Cortés, et al.. (2013). Phase I dose-escalation, open-label study of HSP990 administered orally in adult patients with advanced solid malignancies.. Journal of Clinical Oncology. 31(15_suppl). 2561–2561. 4 indexed citations
7.
Lajoie‐Mazenc, Isabelle, Bettina Couderc, Yann Bergé, et al.. (2013). RhoB modifies estrogen responses in breast cancer cells by influencing expression of the estrogen receptor. Breast Cancer Research. 15(1). R6–R6. 27 indexed citations
8.
9.
Cassier, Philippe A., Nicolas Penel, Christine Chevreau, et al.. (2012). Efficacy and safety of panobinostat (LBH-589), a histone-deacetylase inhibitor (HDACi), in patients (pts) with advanced, previously treated soft tissue sarcoma (STS) and sex cord tumors (SCT): A study from the French Sarcoma Group.. Journal of Clinical Oncology. 30(15_suppl). 10027–10027. 1 indexed citations
10.
Hollebecque, Antoine, Rastislav Bahleda, Yann Bergé, et al.. (2012). Phase I trial to assess the safety and pharmacokinetics of afatinib and weekly vinorelbine in patients with advanced solid tumors.. Journal of Clinical Oncology. 30(15_suppl). 3104–3104. 6 indexed citations
11.
Isambert, Nicolás, Antoine Hollebecque, Yann Bergé, et al.. (2012). A phase I study of Debio 0932, an oral HSP90 inhibitor, in patients with solid tumors.. Journal of Clinical Oncology. 30(15_suppl). 3026–3026. 4 indexed citations
12.
Bergé, Yann, Ben Allal, Thomas Filleron, et al.. (2011). Formation of the eIF4F Translation–Initiation Complex Determines Sensitivity to Anticancer Drugs Targeting the EGFR and HER2 Receptors. Cancer Research. 71(12). 4068–4073. 45 indexed citations
13.
Cioffi, Angela, Antoîne Italiano, Nicolas Penel, et al.. (2011). Metastatic epitheloid hemangioendothelioma (EHE): Role of systemic therapy and survival.. Journal of Clinical Oncology. 29(15_suppl). 10079–10079. 11 indexed citations
14.
Paz‐Ares, Luis, Carlos Gomez‐Roca, Jean‐Pierre Delord, et al.. (2011). Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors. Journal of Clinical Oncology. 29(28). 3783–3790. 67 indexed citations
15.
Blesius, Aurore, Philippe A. Cassier, I. L. Ray-Coquard, et al.. (2011). Who are the long responders to imatinib (IM) in patients with advanced GIST? Results of the BFR14 prospective French Sarcoma Group randomized phase III trial.. Journal of Clinical Oncology. 29(15_suppl). 10048–10048. 16 indexed citations
16.
Bahleda, Rastislav, J.C. Soria, Yann Bergé, et al.. (2011). Phase I trial assessing safety and pharmacokinetics of afatinib (BIBW 2992) with intravenous weekly vinorelbine in advanced solid tumors.. Journal of Clinical Oncology. 29(15_suppl). 2585–2585. 12 indexed citations
17.
Awada, Ahmad, Nadine Houédé, J.P. Delord, et al.. (2010). 374 Clinical, pharmacokinetic (PK) and pharmacodynamic (PD) results of first-in-man phase I trial of the orally available MEK-inhibitor MSC1936369 (AS703026) in patients (pts) with advanced solid tumors. European Journal of Cancer Supplements. 8(7). 118–118. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yu Kataoka Breakdown of academic impact, for papers by Greg Friberg Breakdown of academic impact, for papers by Laura Kirby Breakdown of academic impact, for papers by Ju-Hee Bang Breakdown of academic impact, for papers by J. Harrison Howard Breakdown of academic impact, for papers by Bruce McCall Breakdown of academic impact, for papers by Matthew R. Strickland Breakdown of academic impact, for papers by Davide Bosso Breakdown of academic impact, for papers by Tim Perera Breakdown of academic impact, for papers by Andrej Valkov
Rankless by CCL
2026